Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | CCR1 | P32246 | 2/20 | 0.46 |
| ▸ | CCR5 | P51681 | 2/20 | 0.46 |
| ▸ | CCR8 | P51685 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | METAP1 | P53582 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.46 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 6/20 | 0.43 |
| ▸ | TP53 | P04637 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1456116 | 0.89 | KDM4E (0.56) | KDM4ELMNAPOLBCCR1CCR5 | |
| SCHEMBL5789792 | 0.81 | PCSK9 (0.44) | KDM4ELMNAPOLBCYP1A2NPC1 | |
| SCHEMBL4031586 | 0.73 | POLB (0.46) | KDM4EPOLBSMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL5163455 | 0.73 | KDM4E (0.50) | KDM4ELMNAPOLBCCR1CCR5 | |
| SCHEMBL17554510 | 0.73 | POLB (0.46) | KDM4EPOLBSMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL12528725 | 0.73 | SMN1; SMN2 (0.48) | KDM4EPOLBCYP1A2SMN1; SMN2TSHR | |
| Dipyridyl SCHEMBL6885910 | 0.70 | KDM4E (0.93) | KDM4ELMNAPOLBCCR1CCR5 | |
| Dipyridyl SCHEMBL8655605 | 0.70 | KDM4E (0.93) | KDM4ELMNAPOLBCCR1CCR5 | |
| Dipyridyl SCHEMBL29907716 | 0.67 | KDM4E (1.00) | KDM4ELMNAPOLBCCR1CCR5 | |
| Dipyridyl SCHEMBL3711450 | 0.67 | KDM4E (1.00) | KDM4ELMNAPOLBCCR1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202840-B2 | Compounds for the treatment or alleviation of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2025-01-21 | — | — | US | disclosed |
| EP-3735411-B1 | 1,3,4,5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER`S DISEASE | AC IMMUNE SA (CH) | 2024-07-10 | — | — | EP | disclosed |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2023-11-14 | — | — | US | disclosed |
| EP-3802528-B1 | NOVEL COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES | AC IMMUNE SA (CH) | 2022-07-06 | — | — | EP | disclosed |
| US-20220127263-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | AC IMMUNE SA (CH) | 2022-04-28 | — | — | US | disclosed |
| EP-3941477-A1 | NOVEL COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES | AC Immune SA (CH) | 2022-01-26 | — | — | EP | disclosed |
| CN-113453688-A | Novel compounds for treating, reducing or preventing conditions associated with Tau aggregates | AC免疫有限公司 | 2021-09-28 | — | — | CN | disclosed |
| US-20210214371-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | AC IMMUNE SA (CH) | 2021-07-15 | — | — | US | disclosed |
| EP-3802528-A1 | NOVEL COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES | AC Immune SA (CH) | 2021-04-14 | — | — | EP | disclosed |
| CN-112313230-A | Novel compounds for treating, alleviating or preventing conditions associated with Tau aggregates | AC免疫有限公司 | 2021-02-02 | — | — | CN | disclosed |
| WO-2019233745-A1 | NOVEL COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES | AC IMMUNE SA (CH) | 2019-12-12 | — | — | WO | disclosed |
| US-20190211012-A1 | Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2019-07-11 | — | — | US | disclosed |
| US-8853391-B2 | Tricyclic azaindoles | MERCK PATENT GMBH (DE) | 2014-10-07 | — | — | US | disclosed |
| US-20120022060-A1 | Tricyclic Azaindoles | MERCK PATENT GMBH (DE) | 2012-01-26 | — | — | US | disclosed |
| EP-2367822-A1 | TRICYCLIC AZAINDOLES | Merck Patent GmbH (DE) | 2011-09-28 | — | — | EP | disclosed |
| EP-2295428-A2 | Linear pyridazine and pyrrolic compounds, methods of preparation and applications | Centre National de la Recherche Scientifique (CNRS) (FR) | 2011-03-16 | — | — | EP | disclosed |
| WO-2010080253-A1 | TRICYCLIC AZAINDOLES | MERCK PATENT GMBH (DE) | 2010-07-15 | — | — | WO | disclosed |
| US-20100004443-A1 | LINEAR PYRIDAZINE AND PYRROLE COMPOUNDS, METHOD FOR OBTAINING THEM AND APPLICATIONS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N. (FR) | 2010-01-07 | — | — | US | disclosed |
| EP-2061785-A2 | LINEAR PYRIDAZINE AND PYRROLE COMPOUNDS, PROCESSES FOR OBTAINING THEM AND USES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008012441-A2 | LINEAR PYRIDAZINE AND PYRROLE COMPOUNDS, PROCESSES FOR OBTAINING THEM AND USES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12202840-B2 | Compounds for the treatment or alleviation of disorders associated with Tau aggregates | MAPT, MAP1LC3A, TUBB3 | KDM4E 3850/4885LMNA 2285/4885POLB 2557/4885 |
| US-20210214371-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | MAPT, MAP1LC3A, MAP1LC3B | KDM4E 4066/4885LMNA 2338/4885POLB 2923/4885 |
| US-20190211012-A1 | Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, MAP1LC3B | KDM4E 4066/4885LMNA 2338/4885POLB 2923/4885 |
| US-20220127263-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | MAPT, MAP1LC3A, MAP1LC3B | KDM4E 4066/4885LMNA 2338/4885POLB 2923/4885 |
| US-20100004443-A1 | LINEAR PYRIDAZINE AND PYRROLE COMPOUNDS, METHOD FOR OBTAINING THEM AND APPLICATIONS | PPOX, PNPO, PLPBP | KDM4E 2135/4885LMNA 3500/4885POLB 344/4885 |
| US-20120022060-A1 | Tricyclic Azaindoles | AZI2, DCK, PPP2CA | KDM4E 1192/4885LMNA 3834/4885POLB 1455/4885 |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, TUBB3 | KDM4E 4065/4885LMNA 2017/4885POLB 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.